Sun Pharmaceutical Industries Limited concluded its Board of Directors meeting on July 31, 2026, at its registered office in Mumbai. The session commenced at 10:50 A.M., was adjourned for a break, and subsequently resumed and concluded at 3:40 P.M. The company’s filing serves as a procedural confirmation of the meeting’s end rather than a disclosure of material decisions, with no specific resolutions, financial results, or strategic approvals announced in this communication.

The notice was issued further to an earlier communication dated July 31, 2026, regarding the convening of the board session. Investors and stakeholders are advised to monitor subsequent filings for details on any actions taken during the deliberations, such as dividend declarations, capital allocation plans, or governance changes. As no material information was disclosed in this specific filing, there are no immediate implications for share price movement or operational strategy based solely on this announcement.

Meeting Details

Anoop Anjanikumar Deshpande, the Company Secretary and Compliance Officer of Sun Pharmaceutical Industries Limited, signed the confirmation of the meeting’s conclusion. His ICSI Membership No. is A23983. The document was digitally signed on July 31, 2026, at 18:13:45 IST.

The market will await further disclosures from the company to understand the outcomes of the deliberations held during the three-hour-plus session. Until such time, the filing remains a routine compliance update confirming the procedural completion of the board meeting.

Sun Pharmaceutical Industries Limited has filed its unaudited financial results for the quarter ended June 30, 2026, with the National Stock Exchange of India Limited and BSE Limited. The disclosure marks the commencement of the company's reporting for FY27, providing stakeholders with an initial view of its performance in the new fiscal year. While the specific financial metrics are detailed in the full results available on the company’s website, the filing ensures regulatory compliance and timely dissemination of material information to investors.

The Board of Directors approved the results in a meeting held on July 31, 2026. Managing Director Kirti Ganorkar signed off on the communication, which was subsequently filed with the exchanges as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed entities to disclose quarterly financial results within seven working days from the close of each quarter.

To further ensure transparency and reach a broader audience, Sun Pharma published newspaper advertisements on August 1, 2026. The advertisements appeared in all editions of Financial Express in English and the Ahmedabad Edition of Financial Express in Gujarati. These publications serve as a formal intimation under Regulation 30 of the SEBI LODR Regulations, ensuring that retail investors who may not track digital filings are also informed of the results.

Key Details of the Filing

Investors can access the complete unaudited financial statements, including standalone and consolidated figures, on the company’s website at www.sunpharma.com . The results are also available on the websites of the stock exchanges, www.bseindia.com and www.nseindia.com . A QR code provided in the advertisement allows users to scan and directly access the detailed financial report.

The filing process was overseen by Anoop Deshpande, the Company Secretary and Compliance Officer, who digitally signed the intimation on August 1, 2026. The company emphasized that the advertisement is for information purposes only and does not constitute an offer or invitation to purchase or sell securities. As with all quarterly filings, these results are subject to limited review by statutory auditors before final audit at the end of the fiscal year.